Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis.

Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. Abstract Text:

    gary fanjiangGary Fanjiang,george h russellGeorge H Russell,aubrey j katzAubrey J Katz,

    OBJECTIVES: We evaluated the response to infliximab in pediatric patients with ulcerative colitis (UC) and their long-term follow-up. We expanded our previous study of 14 patients and furthermore evaluated the success of weaning patients from infliximab. PATIENTS AND METHODS: We reviewed the charts of 27 pediatric patients with UC who were treated with infliximab instead of undergoing a colectomy. Patients with new-onset UC refractory to intravenous steroids for 5 to 10 days and patients with non-steroid-dependent UC with an acute exacerbation were classified as acutely ill (n = 16); patients with chronic steroid-dependent UC were classified as chronically ill (n = 11). The Lichtiger Colitis Activity Index (LCAI) was measured for all patients at baseline and at 1 and 2 months after treatment with infliximab was initiated. Patients were regarded as successfully treated if they remained off steroids and avoided colectomy. RESULTS: The acutely ill group had a mean LCAI score of 11.4 at induction and 0.3 after 2 months. The chronically ill group had a mean LCAI score of 11.2 at induction and 5.5 after 2 months. Treatment with infliximab was successful in 75% of acutely ill patients and in 27% of chronically ill patients. Infliximab was discontinued in 80% of successfully treated patients (83% of acutely ill, 67% of chronically ill). These patients had an average of 10 infusions and a mean follow-up time of 10 months from their last infliximab infusion. CONCLUSIONS: Our results suggest that infliximab is more effective in acutely ill UC patients than in patients with chronic steroid-dependent UC. In addition, some patients treated with infliximab can be weaned from infliximab and maintain remission.

    Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. Publishing Authors By Initials

    g fanjiangG Fanjiang,gh russellGH Russell,aj katzAJ Katz,

    For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

    PUBMED ID PMID:

    MEDLINE DATE:

    Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. Journal Published:

    PUBLICATION TYPE: Research Support, U.S. Gov't,

    Journal: Journal of pediatric gastroenterology and nutritio

    VOLUME: 44

    Page Numbers: 312-7

    Journal Abbreviation: J. Pediatr. Gastroenterol. Nut

    ISSN: 1536-4801

    DAY: 3

    MONTH: Mar

    YEAR: 2007

    Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8211545

    Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. Keywords Mesh Terms:

    KEYWORDS: Time Factors

    MESH TERMS: therapeutic use

    Chemical & Substance for Abstract: Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. Information

    Substance Name: infliximab

    Registry Number: 0

    Grant and Affiliation Information for Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis.

    AFFILIATION: Department of Pediatric Gastroenterology & Nutrition, Massachusetts General Hospital for Children, Boston 02114, USA. gfanjiang@partners.org

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States AHRQ

    GRANT: T32-HS00060

    ACRONYM: HS

    MEDLINETA: J Pediatr Gastroenterol Nutr

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News